More_on GSK’s dropping 24-valent pneumococcal vaccine—(from FierceBiotech): https://www.fiercebiotech.com/biotech/gsk-axes-vaccine-21b-deal-switching-preclinical-successor-over-increased-competition A spokesperson for GSK said “increased competition” drove the decision.